Journal profile · Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Journal for ImmunoTherapy of Cancer
ISSN 2051-1426 · BMJ PUBLISHING GROUP · UNITED STATES · Founded 2013
Journal for ImmunoTherapy of Cancer: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 10.95; fully open access; APC charged, amount not published; review about 18 weeks (community reports); acceptance rate 21% (journal website); 704 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal for ImmunoTherapy of Cancer is published by BMJ PUBLISHING GROUP and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and CAR-T cell therapy research, together about 55.2% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Acceptance rate:21%Impact Factor (JCR):11.7IF rank (Oncology):30/333IF rank (Immunology):9/183Citescore:16.6Total content views:1.06 millionMore journal metricsHow we get these metrics*median number of days Aims & scope Editorial board Ownership Journal information Journal Statistics 2025 Contact information For authors Advertising Rights and permissions Affiliations
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Editor-in-chief Michael T. LotzePublisher website
Editorial board by country: 3 in mainland China (about 7%); most named United States 23, Mainland China 3, Germany 3, Netherlands 3, Spain 2 (41 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine26.6%
- Immunotherapy and Immune ResponsesImmunology and Microbiology15%
- CAR-T cell therapy researchMedicine13.6%
- Immune Cell Function and InteractionImmunology and Microbiology6.4%
- Immune cells in cancerImmunology and Microbiology6.3%
- Monoclonal and Polyclonal Antibodies ResearchMedicine3.5%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology3.4%
- Ferroptosis and cancer prognosisMedicine3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
| Minor | Immunology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 10.95LetPub ·
- Impact factor (publisher)
- 11.7Publisher website ·
- CiteScore 2026-06
- 16.6LetPub ·
- CiteScore (publisher)
- 16.6Publisher website ·
- SJR 2026-06
- 4.11LetPub ·
- SNIP 2026-06
- 1.93LetPub ·
- h-index
- 36LetPub ·
- h-index
- 186OpenAlex ·
- i10-index
- 3,268OpenAlex ·
- 2-year mean citedness
- 9.87OpenAlex ·
- Self-citation rate
- 3.4%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 587LetPub ·
Articles by year OpenAlex count · 5,882 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 433 | 433 | 461 |
| 2025 | 704 | 704 | 6,000 |
| 2024 | 479 | 479 | 9,491 |
| 2023 | 476 | 476 | 14,531 |
| 2022 | 566 | 566 | 26,185 |
| 2021 | 644 | 644 | 34,270 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 18 weeksLetPub ·
- Acceptance rate (publisher)
- 21%Publisher website ·
- Submission to publication (journal-reported)
- about 24 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | GBP 2,390 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,490 / EUR 2,040 / GBP 1,690 | — | — | |
| LetPub | USD 3,180 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted5
- case studiescase studiesLength not stated
- literature reviewsliterature reviewsLength not stated
- position papersposition papersLength not stated
- practice guidelinespractice guidelinesLength not stated
- researchhigh quality researchLength not stated
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BMJ PUBLISHING GROUP
- Country or region
- UNITED STATES
- Language
- English
- Founded
- 2013
- ISSN
- 2051-1426
- Society / sponsor
- Society for Immunotherapy of Cancer
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal for ImmunoTherapy of Cancer
What CAS zone is Journal for ImmunoTherapy of Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal for ImmunoTherapy of Cancer is in Zone 1 of Medicine, and in Zone 1 of the minor category Immunology / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal for ImmunoTherapy of Cancer?
The latest impact factor listed by LetPub is 10.95; CiteScore 16.6, h-index 186.
How long does peer review take at Journal for ImmunoTherapy of Cancer?
Authors report an average review time of about 18 weeks; the journal's website gives an acceptance rate of 21%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal for ImmunoTherapy of Cancer based?
Of the 41 board members whose country the journal's board page names, 3 (about 7%) are in mainland China; the countries named most often are United States (23), Mainland China (3) and Germany (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal for ImmunoTherapy of Cancer?
According to LetPub and DOAJ records, Journal for ImmunoTherapy of Cancer is indexed in SCIE, Scopus and DOAJ.
Is Journal for ImmunoTherapy of Cancer open access, and what is the APC?
Journal for ImmunoTherapy of Cancer is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .